Pharmacology Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacology, including details on pharmacogenomics, drug development, new medications.

Volume 3 (2007), Issue 5 (May)

1. Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing.
   J Pharm Sci, 96(6): 1548-63. [Abstract] [Full-text]
2. Structure-based design of a pathway-specific nuclear import inhibitor.
   Nat Struct Mol Biol, 14(5): 452-4. [Abstract] [Full-text]
3. Pharmacogenetics of metformin response: a step in the path toward personalized medicine.
   J Clin Invest, 117(5): 1226-9. [Abstract] [Full-text]
4. Development of TLR9 agonists for cancer therapy.
   J Clin Invest, 117(5): 1184-94. [Abstract] [Full-text]
5. First-generation blood substitutes: what have we learned? Biochemical and physiological perspectives.
   Expert Opin Biol Ther, 7(5): 665-75. [Abstract] [Full-text]
6. Rational approaches to developing an anti-disease vaccine against malaria.
   Microbes Infect, 9(6): 784-91. [Abstract] [Full-text]
7. Human hepatocytes: isolation, cryopreservation and applications in drug development.
   Chem Biol Interact, 168(1): 16-29. [Abstract] [Full-text]
8. The pivotal role of hepatocytes in drug discovery.
   Chem Biol Interact, 168(1): 2-15. [Abstract] [Full-text]
9. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.
   Cancer Res, 67(9): 4028-33. [Abstract] [Full-text]
10. Quantitative structure activity relationship model for predicting the depletion percentage of skin allergic chemical substances of glutathione.
    Anal Chim Acta, 591(2): 255-64. [Abstract] [Full-text]
11. Pharmacogenomics and its implications for autoimmune disease.
    J Autoimmun, 28(2): 122-8. [Abstract] [Full-text]
12. Ancestry and pharmacogenetics of antileukemic drug toxicity.
    Blood, 109(10): 4151-7. [Abstract] [Full-text]
13. Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity.
    Blood, 109(10): 4450-60. [Abstract] [Full-text]
14. Computational design and experimental discovery of an antiestrogenic peptide derived from alpha-fetoprotein.
    J Am Chem Soc, 129(19): 6263-8. [Abstract] [Full-text]
15. Suppressive effect of herbal medicine saikokeishito on acinar cell apoptosis in rat spontaneous chronic pancreatitis.
    Pancreatology, 7(1): 28-36. [Abstract] [Full-text]
16. Prevalidation of potential protein biomarkers in toxicology using iTRAQ reagent technology.
    Proteomics, 7(10): 1564-74. [Abstract] [Full-text]
17. Enzymes and pharmacogenetics of cardiovascular drugs.
    Clin Chim Acta, 381(1): 26-31. [Abstract] [Full-text]
18. Personalized medicine: elusive dream or imminent reality?
    Clin Pharmacol Ther, 81(6): 807-16. [Abstract] [Full-text]
19. In vivo molecular imaging biomarkers: clinical pharmacology's new "PET"?
    Clin Pharmacol Ther, 81(6): 792-5. [Abstract] [Full-text]
20. Drug discovery in the metabolic syndrome: context and some recent developments.
    Expert Opin Ther Targets, 11(6): 801-8. [Abstract] [Full-text]
21. Clinical pharmacology education and training at the National Institutes of Health.
    Clin Pharmacol Ther, 81(6): 907-9. [Abstract] [Full-text]
22. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
    Clin Pharmacol Ther, 81(6): 899-902. [Abstract] [Full-text]
23. Antibody engineering and modification technologies.
    Biomol Eng, 24(2): 201-15. [Abstract] [Full-text]
24. Influence of wettability and surface activity on release behavior of hydrophilic substances from lipid matrices.
    J Control Release, 119(2): 173-81. [Abstract] [Full-text]
25. Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
    Chem Res Toxicol, 20(5): 715-20. [Abstract] [Full-text]
26. Quantitative structure-imprinting factor relationship of molecularly imprinted polymers.
    Biosens Bioelectron, 22(12): 3309-17. [Abstract] [Full-text]
27. Fast-disintegrating sublingual epinephrine tablets: effect of tablet dimensions on tablet characteristics.
    Drug Dev Ind Pharm, 33(5): 523-30. [Abstract] [Full-text]
28. Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan.
    Pharmacogenomics J, 7(3): 180-9. [Abstract] [Full-text]
29. SHOP: scaffold HOPping by GRID-based similarity searches.
    J Med Chem, 50(11): 2708-17. [Abstract] [Full-text]
30. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors.
    ACS Chem Biol, 2(5): 329-36. [Abstract] [Full-text]
31. The use of proteomics to identify novel therapeutic targets for the treatment of disease.
    J Pharm Pharmacol, 59(5): 609-28. [Abstract] [Full-text]
32. Strategies for developing protein tyrosine phosphatase inhibitors.
    Methods, 42(3): 250-60. [Abstract] [Full-text]
33. QSAR study of angiotensin II antagonists using robust boosting partial least squares regression.
    Anal Chim Acta, 593(1): 68-74. [Abstract] [Full-text]
34. Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology.
    Toxicology, 236(1): 1-6. [Abstract] [Full-text]
35. Discovery of novel inhibitors targeting enoyl-acyl carrier protein reductase in Plasmodium falciparum by structure-based virtual screening.
    Biochem Biophys Res Commun, 358(3): 686-91. [Abstract] [Full-text]

© 2005-2008 Pharmacology Research Today. All Rights Reserved.